A Post-marketing Study to Evaluate a Novel Surgical Monitoring Technique Using the EARP Nerve Cuff in TLIF Surgery.
Launched by RETROPSOAS TECHNOLOGIES, LLC · Jan 3, 2024
Trial Information
Current as of November 11, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new surgical monitoring technique called the EARP Nerve Cuff, which will be used during a specific type of back surgery known as Transforaminal Lumbar Interbody Fusion (TLIF). The goal is to see how well this new device works compared to standard nerve monitoring tools that surgeons typically use. By comparing these devices, the researchers hope to determine which one is safer and better at monitoring the nerves during surgery.
To participate in this trial, you need to be between the ages of 18 and 80 and scheduled for TLIF surgery at the L2 to S1 levels of your spine. Certain medical conditions or situations, like being pregnant or having specific allergies, may prevent you from joining. If you decide to take part, you can expect to have the new monitoring device used alongside the standard tools during your surgery, and the effectiveness and safety of both will be carefully evaluated. This study is currently looking for participants, and your involvement could help improve the safety of future surgeries.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • • Undergoing TLIF between L2-S1
- Exclusion Criteria:
- • Requiring TLIF surgery only at the L5-S1 level
- • Acute lumbar spine trauma requiring immediate intervention
- • Allergy or contraindication to propofol
- • Lower extremity amputation
- • Significant lower extremity edema noted on clinical exam
- • Current treatment with chemotherapy, radiation, or immunosuppression
- • Pregnant, or plans on becoming pregnant in the near future
- • History of allergy to titanium, platinum, aluminum, stainless steel, or silicon
About Retropsoas Technologies, Llc
Retropsoas Technologies, LLC is an innovative clinical trial sponsor dedicated to advancing therapeutic solutions in the field of musculoskeletal health. With a focus on developing cutting-edge technologies and treatment modalities, the company aims to enhance patient outcomes through rigorous research and clinical evaluation. By leveraging a multidisciplinary approach and fostering strategic partnerships, Retropsoas Technologies is committed to delivering evidence-based interventions that address unmet medical needs, ultimately contributing to the improvement of quality of life for patients suffering from various musculoskeletal conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pittsburgh, Pennsylvania, United States
New Haven, Connecticut, United States
Philadelphia, Pennsylvania, United States
Patients applied
Trial Officials
Nicholas Poulos, MD
Study Director
Retropsoas Technologies, LLC
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported